Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
In Vitro Diagnostics

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2070354

Cover Image

PUBLISHER: MarketsandMarkets | PRODUCT CODE: 2070354

Transplant Diagnostics Market by Product & Service (Instrument, Software), Technology (PCR, NGS), Application [Diagnostic (Infectious Disease, HLA) Research], Type [Solid Organ (Heart), Bone Marrow], End User (Hospital) & Region -Global Forecast to 2031

PUBLISHED:
PAGES: 484 Pages
DELIVERY TIME: 1-2 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
PDF (Single User License)
USD 4950
PDF (5-user License)
USD 6650
PDF (Corporate License)
USD 8150
PDF (Global License)
USD 10000

Add to Cart

Description

Table of Contents

List of Tables

The market for transplant diagnostics is valued at around USD 5.61 billion in 2026 and is expected to reach USD 8.14 billion by 2031, at a growth rate of 7.8%. The growing number of organ transplantation procedures is driving the demand for various testing methods, including donor-recipient compatibility testing, histocompatibility testing, infectious disease testing, and blood profiling.

Scope of the Report
Years Considered for the Study2026-2031
Base Year2025
Forecast Period2026-2031
Units ConsideredValue (USD billion)
SegmentsProduct & Service, Technology, Application, Type, and End User
Regions coveredNorth America, Europe, Asia Pacific, Latin America, and the Middle East & Africa

Additionally, the rising adoption of molecular diagnostic technologies, such as PCR (polymerase chain reaction) and NGS (next-generation sequencing), is further fueling market growth. These technologies offer advantages such as high procedural efficacy, quick turnaround times, and real-time sample analysis. Furthermore, increasing awareness of the benefits of molecular diagnostic techniques in reducing the risk of graft rejection and improving transplantation outcomes is also contributing to market expansion.

Transplant Diagnostics Market - IMG1

"The diagnostic applications segment is expected to witness the fastest growth rate in the transplant diagnostics market, by application, during the forecast period."

Based on application, the transplant diagnostics market is divided into diagnostic applications and research applications. In 2025, the diagnostic applications segment is expected to experience the fastest growth in the transplant diagnostics market. This growth is primarily due to advancements in molecular assay techniques and the increasing use of these procedures for pathogen detection and histocompatibility testing. Additionally, the rising incidence of chronic diseases that require transplantation is boosting demand for transplant diagnostic products and services. There is also a greater risk of genetic disorders and pathogen infections following transplantation, which supports the need for effective donor-recipient compatibility testing and post-transplant monitoring. Furthermore, growing awareness of the importance of accurate transplant diagnostics in reducing the risks of graft rejection and improving transplantation outcomes is contributing to the expansion of this segment.

"The solid organ transplantation segment accounted for the largest market share in the transplant diagnostics market, by type, in 2025."

Based on transplant type, the transplant diagnostics market is divided into solid organ transplantation, stem cell transplantation, soft tissue transplantation, and bone marrow transplantation. In 2025, the solid organ transplantation segment led the transplant diagnostics market. This segment's significant share is mainly due to the growing use of transplant diagnostic products for various purposes, including donor-recipient compatibility testing, infectious disease testing, histocompatibility testing, genomic profiling, and blood profiling during solid organ transplantation procedures. Moreover, the increasing number of organ transplantation procedures, supportive government regulations, the rising prevalence of chronic diseases and disorders requiring transplantation, and technological advancements in transplant diagnostics are further contributing to the growth of this segment.

"The Asia Pacific is the fastest-growing market for transplant diagnostics during the forecast period."

Based on region, the transplant diagnostics market is divided into North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2025, the Asia Pacific region is expected to see the fastest growth in the transplant diagnostics market. This growth is primarily driven by increased healthcare spending, rapid advances in healthcare infrastructure, greater adoption of advanced diagnostic technologies, and significant economic growth in emerging Asia-Pacific countries. Additionally, factors such as a rising elderly population, an increased prevalence of chronic diseases requiring transplants, and growing government initiatives to modernize healthcare systems in countries like China, India, and Japan are further supporting market expansion. Furthermore, Japan's provision of universal healthcare coverage for transplantation-related procedures and the burgeoning medical tourism industry across Asia Pacific countries are also contributing to the growth of the transplant diagnostics market in the region.

The breakup of the profile of primary participants in the transplant diagnostics market:

  • By Company Type: Tier 1 (40%), Tier 2 (30%), and Tier 3 (30%)
  • By Designation: C-level Executives (27%), Directors (18%), and Other Designations (55%)
  • By Region: North America (51%), Europe (21%), Asia Pacific (18%), Latin America (6%), and the Middle East & Africa (4%)

The key players in the molecular infectious disease testing market are Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), bioMerieux (France), Becton, Dickinson and Company (US), Illumina, Inc. (US), DiaSorin S.p.A. (Italy), CAREDX, INC. (US), Werfen (Spain), Hologic, Inc. (US), Merck KGaA (Germany), Eurobio Scientific (France), Biofortuna Limited (UK), BAG Diagnostics GmbH (Germany), Fujirebio (Japan), HistoGenetics LLC (US), PacBio (US), TBG Biotechnology Corp (Taiwan), Scisco Genetics, Inc. (US), inno-train Diagnostik GmbH (Germany), Bionobis (France), Takara Bio Inc. (Japan), Krishgen Biosystems Private Limited (India), and Prolmmune Ltd. (UK).

Research Coverage:

This research report categorizes the transplant diagnostics market by product & service (reagents & consumables, instruments, and software & services), technology {molecular assays [PCR-based molecular assays (real-time PCR, sequence-specific primer-PCR, sequence-specific oligonucleotide-PCR, and other PCR-based molecular assays), sequencing-based molecular assays (Sanger sequencing, next-generation sequencing, and other sequencing-based molecular assays)] and non-molecular assays}, application {diagnostic applications [pre-transplantation diagnostics (infectious disease testing, histocompatibility testing, and blood profiling) and post-transplantation diagnostics] and research applications}, transplant type [solid organ transplantation (kidney transplantation, liver transplantation, heart transplantation, lung transplantation, pancreas transplantation, and other organ transplantation), stem cell transplantation, soft tissue transplantation, and bone marrow transplantation], end user (hospitals & transplant centers, research & academic institutes, and independent reference laboratories), and region (North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa). This report provides a comprehensive overview of the key factors driving growth in the transplant diagnostics market, including drivers, restraints, opportunities, and challenges. It offers an in-depth analysis of the major industry players, highlighting their business models, available solutions, key strategies, recent acquisitions, and agreements. Additionally, the report includes a competitive analysis of emerging startups in the transplant diagnostics market.

Reasons to Buy this Report:

The report will assist market leaders and new entrants in the transplant diagnostics industry by providing estimated revenue figures for the overall market and its subsegments. It aims to help stakeholders understand the competitive landscape, allowing them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into the market dynamics, including key drivers, restraints, opportunities, and challenges.

The report provides insights into the following pointers:

  • Analysis of key drivers (increasing number of transplant procedures, advancements in molecular diagnostic technologies, increasing public-private funding for transplant research, and rising prevalence of infectious diseases), restraints (high cost of advanced molecular diagnostic techniques and limited access to advanced transplant diagnostic infrastructure in emerging economies), opportunities (increasing adoption of cross-matching and chimerism testing and growing awareness regarding organ donation and transplantation), and challenges (gap between organ donor availability and transplant demand) influencing the growth of the transplant diagnostics market.
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the transplant diagnostics market.
  • Market Development: Comprehensive information about lucrative markets; the report analyzes the transplant diagnostics market across varied regions.
  • Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the transplant diagnostics market.
  • Competitive Assessment: In-depth assessment of market shares, growth strategies, and product offerings of leading players like Thermo Fisher Scientific Inc. (US), F. Hoffmann-La Roche Ltd (Switzerland), Bio-Rad Laboratories, Inc. (US), QIAGEN N.V. (Netherlands), and bioMerieux (France).
Show more
Product Code: MD 4870

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 STUDY OBJECTIVES
  • 1.2 MARKET DEFINITION
  • 1.3 STUDY SCOPE
    • 1.3.1 MARKETS COVERED & REGIONAL SCOPE
    • 1.3.2 INCLUSIONS & EXCLUSIONS
    • 1.3.3 YEARS CONSIDERED
  • 1.4 CURRENCY CONSIDERED
  • 1.5 STAKEHOLDERS
  • 1.6 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

  • 2.1 KEY INSIGHTS & MARKET HIGHLIGHTS
  • 2.2 KEY MARKET PARTICIPANTS: INSIGHTS & STRATEGIC DEVELOPMENTS
  • 2.3 DISRUPTIVE TRENDS SHAPING MARKET GROWTH
  • 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
  • 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

  • 3.1 TRANSPLANT DIAGNOSTICS MARKET OVERVIEW
  • 3.2 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2026 VS. 2031
  • 3.3 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2026 VS. 2031
  • 3.4 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2026 VS. 2031
  • 3.5 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2026 VS. 2031
  • 3.6 TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2026 VS. 2031
  • 3.7 TRANSPLANT DIAGNOSTICS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

  • 4.1 INTRODUCTION
  • 4.2 MARKET DYNAMICS
    • 4.2.1 DRIVERS
      • 4.2.1.1 Increasing number of transplant procedures
      • 4.2.1.2 Advancements in molecular diagnostic technologies
      • 4.2.1.3 Increasing public-private funding for transplant research
      • 4.2.1.4 Rising incidence of chronic diseases
    • 4.2.2 RESTRAINTS
      • 4.2.2.1 High cost of instruments and consumables
      • 4.2.2.2 Limited access to advanced transplant diagnostic infrastructure in emerging economies
    • 4.2.3 OPPORTUNITIES
      • 4.2.3.1 Increasing adoption of cross-matching and chimerism testing
      • 4.2.3.2 Growing awareness regarding organ donation and transplantation
    • 4.2.4 CHALLENGES
      • 4.2.4.1 Gap between organ donor availability and transplant demand
  • 4.3 UNMET NEEDS & WHITE SPACES
    • 4.3.1 UNMET NEEDS IN TRANSPLANT DIAGNOSTICS MARKET
    • 4.3.2 WHITE SPACE OPPORTUNITIES
  • 4.4 INTERCONNECTED MARKETS & CROSS-SECTOR OPPORTUNITIES
    • 4.4.1 INTERCONNECTED MARKETS
    • 4.4.2 CROSS-SECTOR OPPORTUNITIES
  • 4.5 STRATEGIC MOVES BY TIER 1/2/3 PLAYERS
    • 4.5.1 KEY MOVES & STRATEGIC FOCUS

5 INDUSTRY TRENDS

  • 5.1 PORTER'S FIVE FORCES ANALYSIS
    • 5.1.1 BARGAINING POWER OF SUPPLIERS
    • 5.1.2 BARGAINING POWER OF BUYERS
    • 5.1.3 THREAT OF NEW ENTRANTS
    • 5.1.4 THREAT OF SUBSTITUTES
    • 5.1.5 INTENSITY OF COMPETITIVE RIVALRY
  • 5.2 MACROECONOMIC INDICATORS
    • 5.2.1 INTRODUCTION
    • 5.2.2 GDP TRENDS & FORECAST
  • 5.3 SUPPLY CHAIN ANALYSIS
  • 5.4 VALUE CHAIN ANALYSIS
  • 5.5 ECOSYSTEM ANALYSIS
  • 5.6 PRICING ANALYSIS
    • 5.6.1 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2024-2026
    • 5.6.2 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY REGION, 2024-2026
  • 5.7 TRADE ANALYSIS
    • 5.7.1 IMPORT SCENARIO (HS CODE 3822)
    • 5.7.2 EXPORT SCENARIO (HS CODE 3822)
  • 5.8 KEY CONFERENCES & EVENTS, 2026-2027
  • 5.9 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • 5.10 INVESTMENT & FUNDING SCENARIO
  • 5.11 IMPACT OF 2025 US TARIFFS ON TRANSPLANT DIAGNOSTICS MARKET
    • 5.11.1 INTRODUCTION
    • 5.11.2 KEY TARIFF RATES
    • 5.11.3 PRICE IMPACT ANALYSIS
    • 5.11.4 IMPACT ON REGION
      • 5.11.4.1 North America
      • 5.11.4.2 Europe
      • 5.11.4.3 Asia Pacific
    • 5.11.5 IMPACT ON END-USE INDUSTRIES
      • 5.11.5.1 Hospitals & transplant centers
      • 5.11.5.2 Research & academic institutes
      • 5.11.5.3 Independent reference laboratories

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, PATENTS, INNOVATIONS, AND FUTURE APPLICATIONS

  • 6.1 KEY EMERGING TECHNOLOGIES
    • 6.1.1 DONOR-DERIVED CELL-FREE DNA (DD-CFDNA)
    • 6.1.2 DIGITAL PCR (DPCR)
  • 6.2 COMPLEMENTARY TECHNOLOGIES
    • 6.2.1 AI IN TRANSPLANT DIAGNOSTICS
    • 6.2.2 BIOINFORMATICS
  • 6.3 ADJACENT TECHNOLOGIES
    • 6.3.1 LIQUID BIOPSY
    • 6.3.2 DIGITAL PATHOLOGY
  • 6.4 TECHNOLOGY/PRODUCT ROADMAP
  • 6.5 PATENT ANALYSIS
    • 6.5.1 LIST OF KEY PATENTS
  • 6.6 FUTURE APPLICATIONS
  • 6.7 IMPACT OF AI/GENERATIVE AI ON TRANSPLANT DIAGNOSTICS MARKET
    • 6.7.1 INTRODUCTION
    • 6.7.2 TOP USE CASES & MARKET POTENTIAL
    • 6.7.3 KEY COMPANIES IMPLEMENTING AI
    • 6.7.4 FUTURE OF AI

7 SUSTAINABILITY & REGULATORY LANDSCAPE

  • 7.1 REGIONAL REGULATIONS & COMPLIANCE
    • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.2 SUSTAINABILITY INITIATIVES
    • 7.2.1 ENVIRONMENTAL IMPACT & ECO-FRIENDLY INITIATIVES IN TRANSPLANT DIAGNOSTICS
      • 7.2.1.1 Eco-friendly initiatives
  • 7.3 SUSTAINABILITY IMPACT & REGULATORY POLICY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

  • 8.1 DECISION-MAKING PROCESS
  • 8.2 BUYER STAKEHOLDERS & BUYING EVALUATION CRITERIA
    • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
    • 8.2.2 BUYING CRITERIA
  • 8.3 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • 8.4 UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • 8.5 MARKET PROFITABILITY
    • 8.5.1 REVENUE POTENTIAL
    • 8.5.2 COST DYNAMICS
    • 8.5.3 MARGIN OPPORTUNITIES IN KEY APPLICATIONS

9 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCTS & SERVICES

  • 9.1 INTRODUCTION
  • 9.2 REAGENTS & CONSUMABLES
    • 9.2.1 REAGENTS & CONSUMABLES TO BE LARGEST AND FASTEST-GROWING SEGMENT IN TRANSPLANT DIAGNOSTICS MARKET
  • 9.3 INSTRUMENTS
    • 9.3.1 INCREASING PUBLIC-PRIVATE INVESTMENTS TO DRIVE MARKET
  • 9.4 SOFTWARE & SERVICES
    • 9.4.1 GROWING AUTOMATION & DIGITALIZATION OF DIAGNOSTIC LABORATORY PROCEDURES TO SUPPORT MARKET GROWTH

10 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY

  • 10.1 INTRODUCTION
  • 10.2 MOLECULAR ASSAYS
    • 10.2.1 PCR-BASED MOLECULAR ASSAYS
      • 10.2.1.1 Real-time PCR
        • 10.2.1.1.1 Smaller sample volume requirements compared to conventional PCR technologies to drive demand
      • 10.2.1.2 Sequence-specific primer-PCR (SSP-PCR)
        • 10.2.1.2.1 Growing public-private investments for research activities to support market growth
      • 10.2.1.3 Sequence-specific oligonucleotide-PCR (SSO-PCR)
        • 10.2.1.3.1 Wide adoption of technique in PCR-based molecular assays market to fuel growth
      • 10.2.1.4 Other PCR-based molecular assays
    • 10.2.2 SEQUENCING-BASED MOLECULAR ASSAYS
      • 10.2.2.1 Sanger sequencing
        • 10.2.2.1.1 Growing demand for high-throughput DNA sequencers in transplant diagnostic applications to drive market
      • 10.2.2.2 Next-generation sequencing (NGS)
        • 10.2.2.2.1 Low turnaround time and high-throughput sequencing to drive adoption of NGS
      • 10.2.2.3 Other sequencing-based molecular assays
  • 10.3 NON-MOLECULAR ASSAYS
    • 10.3.1 REPLACEMENT OF NON-MOLECULAR ASSAY TECHNIQUES WITH DNA-BASED TECHNIQUES TO HAMPER GROWTH

11 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION

  • 11.1 INTRODUCTION
  • 11.2 DIAGNOSTIC APPLICATIONS
    • 11.2.1 PRE-TRANSPLANTATION DIAGNOSTICS
      • 11.2.1.1 Infectious disease testing
        • 11.2.1.1.1 Growing adoption of advanced molecular techniques for pathogen detection to drive market
      • 11.2.1.2 Histocompatibility testing
        • 11.2.1.2.1 Technological advancements and growing R&D activities to propel market
      • 11.2.1.3 Blood profiling
        • 11.2.1.3.1 Growing availability of molecular assay products to support market growth
    • 11.2.2 POST-TRANSPLANTATION DIAGNOSTICS
      • 11.2.2.1 Greater risk of disorders and infections post-transplantation to make diagnostics necessary step
  • 11.3 RESEARCH APPLICATIONS
    • 11.3.1 GROWING FUNDING FOR RESEARCH TO DRIVE MARKET

12 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE

  • 12.1 INTRODUCTION
  • 12.2 SOLID ORGAN TRANSPLANTATION
    • 12.2.1 KIDNEY TRANSPLANTATION
      • 12.2.1.1 Rising prevalence of kidney diseases to drive market
    • 12.2.2 LIVER TRANSPLANTATION
      • 12.2.2.1 Growing patient population with chronic liver diseases and increasing procedural volume to drive market
    • 12.2.3 LUNG TRANSPLANTATION
      • 12.2.3.1 Rising prevalence of chronic lung diseases to drive market
    • 12.2.4 HEART TRANSPLANTATION
      • 12.2.4.1 Increasing prevalence of chronic cardiac diseases to propel market
    • 12.2.5 PANCREAS TRANSPLANTATION
      • 12.2.5.1 Procedural complexity and risk of surgical complications to restrain growth
    • 12.2.6 OTHER SOLID ORGAN TRANSPLANTATION
  • 12.3 STEM CELL TRANSPLANTATION
    • 12.3.1 RISING PROCEDURAL VOLUME AND GROWING RESEARCH ACTIVITIES TO DRIVE MARKET
  • 12.4 SOFT TISSUE TRANSPLANTATION
    • 12.4.1 TECHNOLOGICAL ADVANCEMENTS AND RISING PREVALENCE OF TARGET DISEASES TO DRIVE MARKET
  • 12.5 BONE MARROW TRANSPLANTATION
    • 12.5.1 DEARTH OF WELL-TRAINED SURGEONS TO PERFORM BONE MARROW TRANSPLANTATION TO HINDER GROWTH

13 TRANSPLANT DIAGNOSTICS MARKET, BY END USER

  • 13.1 INTRODUCTION
  • 13.2 INDEPENDENT REFERENCE LABORATORIES
    • 13.2.1 RISING CONSOLIDATION OF DIAGNOSTIC LABORATORIES TO DRIVE MARKET
  • 13.3 HOSPITALS & TRANSPLANT CENTERS
    • 13.3.1 GROWING PURCHASING POWER OF HOSPITALS & TRANSPLANT CENTERS TO SUPPORT MARKET GROWTH
  • 13.4 RESEARCH LABORATORIES & ACADEMIC INSTITUTES
    • 13.4.1 INCREASING INDUSTRY-ACADEMIA COLLABORATIONS IN GENOMICS-BASED TRANSPLANT DIAGNOSTIC RESEARCH TO DRIVE MARKET

14 TRANSPLANT DIAGNOSTICS MARKET, BY REGION

  • 14.1 INTRODUCTION
  • 14.2 NORTH AMERICA
    • 14.2.1 US
      • 14.2.1.1 Growing organ transplantation activity to support market expansion
    • 14.2.2 CANADA
      • 14.2.2.1 Growing transplant programs to support market growth
  • 14.3 EUROPE
    • 14.3.1 GERMANY
      • 14.3.1.1 Expanding donor registry network to fuel market growth
    • 14.3.2 UK
      • 14.3.2.1 Rising transplant demand to support market growth
    • 14.3.3 FRANCE
      • 14.3.3.1 Growing organ donation initiatives to drive growth
    • 14.3.4 ITALY
      • 14.3.4.1 Increasing organ donation rates to drive market growth
    • 14.3.5 SPAIN
      • 14.3.5.1 Strong organ donation system to support market growth
    • 14.3.6 REST OF EUROPE
  • 14.4 ASIA PACIFIC
    • 14.4.1 CHINA
      • 14.4.1.1 Expanding transplantation programs to drive market growth
    • 14.4.2 JAPAN
      • 14.4.2.1 Growing transplant waiting population to support market growth
    • 14.4.3 INDIA
      • 14.4.3.1 Rising transplant procedures to drive market growth
    • 14.4.4 AUSTRALIA
      • 14.4.4.1 Rising number of solid organ transplantation procedures to drive market
    • 14.4.5 SOUTH KOREA
      • 14.4.5.1 Large transplant waiting population to drive market growth
    • 14.4.6 REST OF ASIA PACIFIC
  • 14.5 LATIN AMERICA
    • 14.5.1 BRAZIL
      • 14.5.1.1 Expanding transplant programs to drive market growth
    • 14.5.2 MEXICO
      • 14.5.2.1 Growing medical tourism to support market growth
    • 14.5.3 REST OF LATIN AMERICA
  • 14.6 MIDDLE EAST & AFRICA
    • 14.6.1 UAE
      • 14.6.1.1 Expanding organ donation programs to drive market growth
    • 14.6.2 SAUDI ARABIA
      • 14.6.2.1 Strengthening transplantation capabilities to support market growth
    • 14.6.3 REST OF MIDDLE EAST & AFRICA
    • 14.6.4 US: HEART, LIVER, AND LUNG TRANSPLANTS MARKET VOLUME

15 COMPETITIVE LANDSCAPE

  • 15.1 INTRODUCTION
  • 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
    • 15.2.1 OVERVIEW OF STRATEGIES DEPLOYED BY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET
  • 15.3 REVENUE ANALYSIS, 2023-2025
  • 15.4 MARKET SHARE ANALYSIS, 2025
    • 15.4.1 GLOBAL MARKET SHARE ANALYSIS, 2025
  • 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
    • 15.5.1 STARS
    • 15.5.2 EMERGING LEADERS
    • 15.5.3 PERVASIVE PLAYERS
    • 15.5.4 PARTICIPANTS
    • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
      • 15.5.5.1 Company footprint
      • 15.5.5.2 Region footprint
      • 15.5.5.3 Product & service footprint
      • 15.5.5.4 Application footprint
      • 15.5.5.5 End-user footprint
  • 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
    • 15.6.1 PROGRESSIVE COMPANIES
    • 15.6.2 RESPONSIVE COMPANIES
    • 15.6.3 DYNAMIC COMPANIES
    • 15.6.4 STARTING BLOCKS
    • 15.6.5 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
      • 15.6.5.1 Detailed list of key startups/SMEs
      • 15.6.5.2 Competitive benchmarking of startups/SMEs (1/2)
      • 15.6.5.3 Competitive benchmarking of startups/SMEs (2/2)
  • 15.7 COMPANY VALUATION & FINANCIAL METRICS
    • 15.7.1 FINANCIAL METRICS
    • 15.7.2 COMPANY VALUATION
  • 15.8 BRAND/PRODUCT COMPARISON
  • 15.9 COMPETITIVE SCENARIO
    • 15.9.1 PRODUCT/SERVICE LAUNCHES & APPROVALS
    • 15.9.2 DEALS
    • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

  • 16.1 KEY PLAYERS
    • 16.1.1 THERMO FISHER SCIENTIFIC INC.
      • 16.1.1.1 Business overview
      • 16.1.1.2 Products offered
      • 16.1.1.3 Recent developments
        • 16.1.1.3.1 Product & service launches
        • 16.1.1.3.2 Deals
        • 16.1.1.3.3 Expansions
      • 16.1.1.4 MnM view
        • 16.1.1.4.1 Right to win
        • 16.1.1.4.2 Strategic choices
        • 16.1.1.4.3 Weaknesses & competitive threats
    • 16.1.2 F. HOFFMANN-LA ROCHE LTD.
      • 16.1.2.1 Business overview
      • 16.1.2.2 Products offered
      • 16.1.2.3 Recent developments
        • 16.1.2.3.1 Product launches & approvals
        • 16.1.2.3.2 Deals
      • 16.1.2.4 MnM view
        • 16.1.2.4.1 Right to win
        • 16.1.2.4.2 Strategic choices
        • 16.1.2.4.3 Weaknesses & competitive threats
    • 16.1.3 BIO-RAD LABORATORIES, INC.
      • 16.1.3.1 Business overview
      • 16.1.3.2 Products offered
      • 16.1.3.3 Recent developments
        • 16.1.3.3.1 Product launches
        • 16.1.3.3.2 Deals
      • 16.1.3.4 MnM view
        • 16.1.3.4.1 Right to win
        • 16.1.3.4.2 Strategic choices
        • 16.1.3.4.3 Weaknesses & competitive threats
    • 16.1.4 QIAGEN N.V.
      • 16.1.4.1 Business overview
      • 16.1.4.2 Products offered
      • 16.1.4.3 Recent developments
        • 16.1.4.3.1 Product launches & approvals
        • 16.1.4.3.2 Deals
      • 16.1.4.4 MnM view
        • 16.1.4.4.1 Right to win
        • 16.1.4.4.2 Strategic choices
        • 16.1.4.4.3 Weaknesses & competitive threats
    • 16.1.5 BIOMERIEUX
      • 16.1.5.1 Business overview
      • 16.1.5.2 Products offered
      • 16.1.5.3 Recent developments
        • 16.1.5.3.1 Product launches & approvals
        • 16.1.5.3.2 Deals
      • 16.1.5.4 MnM view
        • 16.1.5.4.1 Right to win
        • 16.1.5.4.2 Strategic choices
        • 16.1.5.4.3 Weaknesses & competitive threats
    • 16.1.6 ILLUMINA, INC.
      • 16.1.6.1 Business overview
      • 16.1.6.2 Products offered
      • 16.1.6.3 Recent developments
        • 16.1.6.3.1 Deals
    • 16.1.7 BECTON, DICKINSON AND COMPANY
      • 16.1.7.1 Business overview
      • 16.1.7.2 Products offered
      • 16.1.7.3 Recent developments
        • 16.1.7.3.1 Deals
    • 16.1.8 CAREDX, INC.
      • 16.1.8.1 Business overview
      • 16.1.8.2 Products offered
      • 16.1.8.3 Recent developments
        • 16.1.8.3.1 Product launches
        • 16.1.8.3.2 Deals
    • 16.1.9 DIASORIN S.P.A.
      • 16.1.9.1 Business overview
      • 16.1.9.2 Products offered
      • 16.1.9.3 Recent developments
        • 16.1.9.3.1 Product launches
        • 16.1.9.3.2 Deals
    • 16.1.10 WERFEN
      • 16.1.10.1 Business overview
      • 16.1.10.2 Products offered
      • 16.1.10.3 Recent developments
        • 16.1.10.3.1 Product launches
        • 16.1.10.3.2 Deals
    • 16.1.11 MERCK KGAA
      • 16.1.11.1 Business overview
      • 16.1.11.2 Products offered
      • 16.1.11.3 Recent developments
        • 16.1.11.3.1 Deals
        • 16.1.11.3.2 Expansions
    • 16.1.12 HOLOGIC, INC.
      • 16.1.12.1 Business overview
      • 16.1.12.2 Products offered
  • 16.2 OTHER PLAYERS
    • 16.2.1 EUROBIO SCIENTIFIC
    • 16.2.2 BIOFORTUNA LIMITED
    • 16.2.3 BAG DIAGNOSTICS GMBH
    • 16.2.4 FUJIREBIO
    • 16.2.5 HISTOGENETICS LLC
    • 16.2.6 PACBIO
    • 16.2.7 TBG BIOTECHNOLOGY CORP
    • 16.2.8 SCISCO GENETICS, INC.
    • 16.2.9 INNO-TRAIN DIAGNOSTIK GMBH
    • 16.2.10 BIONOBIS
    • 16.2.11 TAKARA BIO INC.
    • 16.2.12 KRISHGEN BIOSYSTEMS PRIVATE LIMITED
    • 16.2.13 PROIMMUNE LTD.

17 RESEARCH METHODOLOGY

  • 17.1 RESEARCH DATA
    • 17.1.1 SECONDARY DATA
      • 17.1.1.1 List of secondary sources
      • 17.1.1.2 Key data from secondary sources
    • 17.1.2 PRIMARY DATA
      • 17.1.2.1 List of primary sources
      • 17.1.2.2 Key data from primary sources
      • 17.1.2.3 Key industry insights
      • 17.1.2.4 Breakdown of primary interviews
  • 17.2 MARKET SIZE ESTIMATION
    • 17.2.1 TOTAL MARKET SIZE: TRANSPLANT DIAGNOSTICS MARKET
    • 17.2.2 BOTTOM-UP APPROACH
      • 17.2.2.1 Approach 1: Revenue estimation of key players
      • 17.2.2.2 Approach 2: Study of annual reports and investor presentations
      • 17.2.2.3 Approach 3: Primary interviews
      • 17.2.2.4 Growth forecast
      • 17.2.2.5 CAGR projections
    • 17.2.3 TOP-DOWN APPROACH
  • 17.3 DATA TRIANGULATION
  • 17.4 RESEARCH ASSUMPTIONS
    • 17.4.1 STUDY-RELATED ASSUMPTIONS
  • 17.5 STUDY ASSUMPTIONS
    • 17.5.1 PARAMETRIC ASSUMPTIONS
    • 17.5.2 GROWTH RATE ASSUMPTIONS
  • 17.6 RESEARCH LIMITATIONS
  • 17.7 RISK ASSESSMENT

18 APPENDIX

  • 18.1 DISCUSSION GUIDE
  • 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
  • 18.3 CUSTOMIZATION OPTIONS
  • 18.4 RELATED REPORTS
  • 18.5 AUTHOR DETAILS
Show more
Product Code: MD 4870

List of Tables

  • TABLE 1 TRANSPLANT DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • TABLE 2 GDP PERCENTAGE CHANGE (%), BY KEY COUNTRY, 2023-2030
  • TABLE 3 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 4 EUROPE: MACROECONOMIC INDICATORS
  • TABLE 5 ASIA PACIFIC: MACROECONOMIC INDICATORS
  • TABLE 6 LATIN AMERICA: MACROECONOMIC INDICATORS
  • TABLE 7 MIDDLE EAST & AFRICA: MACROECONOMIC INDICATORS
  • TABLE 8 TRANSPLANT DIAGNOSTICS MARKET: ROLE OF COMPANIES IN ECOSYSTEM
  • TABLE 9 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY KEY PLAYER, 2024-2026 (USD)
  • TABLE 10 AVERAGE SELLING PRICE TREND OF TRANSPLANT DIAGNOSTIC PRODUCTS, BY REGION, 2024-2026 (USD)
  • TABLE 11 IMPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 12 EXPORT DATA FOR HS CODE 3822-COMPLIANT PRODUCTS, BY COUNTRY, 2021-2025 (USD MILLION)
  • TABLE 13 TRANSPLANT DIAGNOSTICS MARKET: KEY CONFERENCES & EVENTS, 2026-2027
  • TABLE 14 US-ADJUSTED RECIPROCAL TARIFF RATES
  • TABLE 15 KEY PATENTS IN TRANSPLANT DIAGNOSTICS MARKET, 2022-2026
  • TABLE 16 KEY COMPANIES IMPLEMENTING AI IN TRANSPLANT DIAGNOSTICS MARKET
  • TABLE 17 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 18 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 19 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 20 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 21 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • TABLE 22 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE (%)
  • TABLE 23 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • TABLE 24 ADOPTION BARRIERS & INTERNAL CHALLENGES
  • TABLE 25 TRANSPLANT DIAGNOSTICS MARKET: UNMET NEEDS IN VARIOUS END-USE INDUSTRIES
  • TABLE 26 TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 27 TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 28 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 29 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 30 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 31 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 32 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAGENTS & CONSUMABLES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 33 TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 34 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 35 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 36 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 37 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 38 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INSTRUMENTS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 39 TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 40 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 41 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 42 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 43 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 44 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFTWARE & SERVICES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 45 TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 46 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 47 TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 48 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 49 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 50 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 51 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 52 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 53 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 54 TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 55 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 56 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 57 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 58 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 59 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 60 TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 61 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 62 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 63 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 64 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 65 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR REAL-TIME PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 66 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 67 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 68 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 69 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 70 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 71 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC PRIMER-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 72 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 73 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 74 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 75 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 76 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 77 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCE-SPECIFIC OLIGONUCLEOTIDE-PCR, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 78 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 79 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 80 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 81 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 82 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 83 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER PCR-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 84 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 85 TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 86 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 87 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 88 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 89 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 90 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 91 TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 92 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 93 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 94 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 95 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 96 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SANGER SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 97 TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 98 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 99 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 100 ASIA PACIFIC: TRANSPLANT DIAGNOSTICSARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 101 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 102 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR NEXT-GENERATION SEQUENCING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 103 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 104 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 105 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 106 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 107 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 108 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SEQUENCING-BASED MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 109 TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 110 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 111 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 112 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 113 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 114 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR NON-MOLECULAR ASSAYS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 115 TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 116 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 117 TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 118 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 119 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 120 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 121 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 122 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 123 TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 124 TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 125 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 126 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 127 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 128 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 129 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 130 TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 131 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 132 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 133 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 134 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 135 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INFECTIOUS DISEASE TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 136 TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 137 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 138 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 139 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 140 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 141 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HISTOCOMPATIBILITY TESTING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 142 TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 143 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 144 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 145 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 146 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 147 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR BLOOD PROFILING, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 148 TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 149 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 150 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 151 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 152 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 153 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR POST-TRANSPLANTATION DIAGNOSTICS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 154 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 155 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 156 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 157 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 158 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 159 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH APPLICATIONS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 160 TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 161 TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 162 TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 163 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 164 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 165 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 166 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 167 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 168 TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 169 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 170 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 171 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 172 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 173 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR KIDNEY TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 174 TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 175 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 176 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 177 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 178 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 179 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR LIVER TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 180 TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 181 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 182 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 183 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 184 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 185 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR LUNG TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 186 TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 187 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 188 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 189 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 190 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 191 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HEART TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 192 TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 193 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 194 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 195 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 196 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 197 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PANCREAS TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 198 TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 199 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 200 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 201 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 202 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 203 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR OTHER SOLID ORGAN TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 204 TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 205 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 206 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 207 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 208 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 209 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR STEM CELL TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 210 TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 211 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 212 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 213 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 214 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 215 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOFT TISSUE TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 216 TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 217 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 218 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 219 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 220 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 221 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR BONE MARROW TRANSPLANTATION, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 222 TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 223 TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 224 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 225 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 226 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 227 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 228 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR INDEPENDENT REFERENCE LABORATORIES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 229 TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 230 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 231 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 232 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 233 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 234 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR HOSPITALS & TRANSPLANT CENTERS, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 235 TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 236 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 237 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 238 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 239 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 240 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR RESEARCH LABORATORIES & ACADEMIC INSTITUTES, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 241 TRANSPLANT DIAGNOSTICS, BY REGION, 2024-2031 (USD MILLION)
  • TABLE 242 NORTH AMERICA: MACROECONOMIC INDICATORS
  • TABLE 243 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 244 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 245 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 246 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 247 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 248 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 249 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 250 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 251 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 252 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 253 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 254 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 255 US: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 256 US: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 257 US: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 258 US: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 259 US: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 260 US: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 261 US: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 262 US: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 263 US: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 264 US: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 265 US: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 266 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 267 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 268 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 269 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 270 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 271 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 272 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 273 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 274 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 275 CANADA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 276 CANADA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 277 MACROECONOMIC INDICATORS FOR EUROPE
  • TABLE 278 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 279 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 280 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 281 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 282 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 283 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 284 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 285 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 286 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 287 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 288 EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 289 EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 290 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 291 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 292 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 293 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 294 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 295 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 296 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 297 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 298 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 299 GERMANY: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 300 GERMANY: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 301 UK: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 302 UK: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 303 UK: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 304 UK: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 305 UK: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 306 UK: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 307 UK: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 308 UK: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 309 UK: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 310 UK: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 311 UK: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 312 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 313 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 314 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 315 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 316 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 317 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 318 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 319 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 320 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 321 FRANCE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 322 FRANCE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 323 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 324 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 325 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 326 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 327 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 328 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 329 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 330 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 331 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 332 ITALY: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 333 ITALY: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 334 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 335 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 336 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 337 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 338 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 339 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 340 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 341 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 342 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 343 SPAIN: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 344 SPAIN: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 345 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 346 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 347 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 348 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 349 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 350 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 351 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 352 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 353 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 354 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 355 REST OF EUROPE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 356 MACROECONOMIC INDICATORS FOR ASIA PACIFIC
  • TABLE 357 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 358 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 359 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 360 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 361 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 362 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 363 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 364 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 365 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 366 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 367 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 368 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 369 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 370 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 371 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 372 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 373 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 374 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 375 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 376 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 377 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 378 CHINA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 379 CHINA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 380 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 381 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 382 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 383 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 384 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 385 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 386 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 387 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 388 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 389 JAPAN: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 390 JAPAN: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 391 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 392 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 393 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 394 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 395 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 396 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 397 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 398 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 399 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 400 INDIA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 401 INDIA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 402 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 403 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 404 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 405 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 406 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 407 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 408 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 409 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 410 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 411 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 412 AUSTRALIA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 413 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 414 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 415 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 416 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 417 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 418 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 419 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 420 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 421 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 422 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 423 SOUTH KOREA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 424 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 425 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 426 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 427 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 428 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 429 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 430 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 431 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 432 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 433 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 434 REST OF ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 435 MACROECONOMIC INDICATORS FOR LATIN AMERICA
  • TABLE 436 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 437 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 438 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 439 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 440 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 441 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 442 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 443 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 444 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 445 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 446 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 447 LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 448 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 449 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 450 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 451 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 452 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 453 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 454 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 455 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 456 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 457 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 458 BRAZIL: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 459 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 460 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 461 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 462 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 463 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 464 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 465 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 466 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 467 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 468 MEXICO: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 469 MEXICO: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 470 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 471 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 472 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 473 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 474 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 475 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 476 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 477 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 478 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 479 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 480 REST OF LATIN AMERICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 481 MACROECONOMIC INDICATORS FOR MIDDLE EAST & AFRICA
  • TABLE 482 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY COUNTRY, 2024-2031 (USD MILLION)
  • TABLE 483 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 484 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 485 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 486 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 487 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 488 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 489 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 490 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 491 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 492 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 493 MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 494 UAE: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 495 UAE: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 496 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 497 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 498 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 499 UAE: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 500 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 501 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 502 UAE: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 503 UAE: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 504 UAE: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 505 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 506 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 507 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 508 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 509 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 510 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 511 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 512 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 513 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 514 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 515 SAUDI ARABIA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 516 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY PRODUCT & SERVICE, 2024-2031 (USD MILLION)
  • TABLE 517 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TECHNOLOGY, 2024-2031 (USD MILLION)
  • TABLE 518 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 519 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PCR-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 520 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SEQUENCING-BASED MOLECULAR ASSAYS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 521 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY APPLICATION, 2024-2031 (USD MILLION)
  • TABLE 522 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR DIAGNOSTIC APPLICATIONS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 523 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR PRE-TRANSPLANTATION DIAGNOSTICS, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 524 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 525 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET FOR SOLID ORGAN TRANSPLANTATION, BY TYPE, 2024-2031 (USD MILLION)
  • TABLE 526 REST OF MIDDLE EAST & AFRICA: TRANSPLANT DIAGNOSTICS MARKET, BY END USER, 2024-2031 (USD MILLION)
  • TABLE 527 US: HEART, LIVER, AND LUNG TRANSPLANTS MARKET, BY TYPE, 2024-2031 (IN THOUSAND)
  • TABLE 528 OVERVIEW OF STRATEGIES DEPLOYED BY KEY COMPANIES IN TRANSPLANT DIAGNOSTICS MARKET, JANUARY 2023-APRIL 2026
  • TABLE 529 TRANSPLANT DIAGNOSTICS MARKET: DEGREE OF COMPETITION
  • TABLE 530 TRANSPLANT DIAGNOSTICS MARKET: REGION FOOTPRINT
  • TABLE 531 TRANSPLANT DIAGNOSTICS MARKET: PRODUCT & SERVICE FOOTPRINT
  • TABLE 532 TRANSPLANT DIAGNOSTICS MARKET: APPLICATION FOOTPRINT
  • TABLE 533 TRANSPLANT DIAGNOSTICS MARKET: END-USER FOOTPRINT
  • TABLE 534 TRANSPLANT DIAGNOSTICS MARKET: DETAILED LIST OF KEY STARTUPS/SMES
  • TABLE 535 TRANSPLANT DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (1/2)
  • TABLE 536 TRANSPLANT DIAGNOSTICS MARKET: COMPETITIVE BENCHMARKING OF STARTUPS/SMES (2/2)
  • TABLE 537 TRANSPLANT DIAGNOSTICS MARKET: PRODUCT/SERVICE LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 538 TRANSPLANT DIAGNOSTICS MARKET: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 539 TRANSPLANT DIAGNOSTICS MARKET: EXPANSION, JANUARY 2023-APRIL 2026
  • TABLE 540 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
  • TABLE 541 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
  • TABLE 542 THERMO FISHER SCIENTIFIC INC.: PRODUCT & SERVICE LAUNCHES, JANUARY 2023-APRIL 2026
  • TABLE 543 THERMO FISHER SCIENTIFIC INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 544 THERMO FISHER SCIENTIFIC INC.: EXPANSIONS, JANUARY 2022-APRIL 2025
  • TABLE 545 F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW
  • TABLE 546 F. HOFFMANN-LA ROCHE LTD.: PRODUCTS OFFERED
  • TABLE 547 F. HOFFMANN-LA ROCHE LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 548 F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 549 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW
  • TABLE 550 BIO-RAD LABORATORIES, INC.: PRODUCTS OFFERED
  • TABLE 551 BIO-RAD LABORATORIES, INC.: PRODUCT LAUNCHES, JANUARY 2023-APRIL 2026
  • TABLE 552 BIO-RAD LABORATORIES, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 553 QIAGEN N.V.: COMPANY OVERVIEW
  • TABLE 554 QIAGEN N.V.: PRODUCTS OFFERED
  • TABLE 555 QIAGEN N.V.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 556 QIAGEN N.V.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 557 BIOMERIEUX: COMPANY OVERVIEW
  • TABLE 558 BIOMERIEUX: PRODUCTS OFFERED
  • TABLE 559 BIOMERIEUX: PRODUCT LAUNCHES & APPROVALS, JANUARY 2023-APRIL 2026
  • TABLE 560 BIOMERIEUX: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 561 ILLUMINA, INC.: COMPANY OVERVIEW
  • TABLE 562 ILLUMINA, INC.: PRODUCTS OFFERED
  • TABLE 563 ILLUMINA, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 564 BECTON, DICKINSON AND COMPANY: COMPANY OVERVIEW
  • TABLE 565 BECTON, DICKINSON AND COMPANY: PRODUCTS OFFERED
  • TABLE 566 BECTON, DICKINSON AND COMPANY: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 567 CAREDX, INC.: COMPANY OVERVIEW
  • TABLE 568 CAREDX, INC.: PRODUCTS OFFERED
  • TABLE 569 CAREDX, INC.: PRODUCT LAUNCHES, JANUARY 2023-APRIL 2026
  • TABLE 570 CAREDX, INC.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 571 DIASORIN S.P.A.: COMPANY OVERVIEW
  • TABLE 572 DIASORIN S.P.A.: PRODUCTS OFFERED
  • TABLE 573 DIASORIN S.P.A.: PRODUCT LAUNCHES, JANUARY 2023-APRIL 2026
  • TABLE 574 DIASORIN S.P.A.: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 575 WERFEN: COMPANY OVERVIEW
  • TABLE 576 WERFEN: PRODUCTS OFFERED
  • TABLE 577 WERFEN: PRODUCT LAUNCHES, JANUARY 2023-APRIL 2026
  • TABLE 578 WERFEN: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 579 MERCK KGAA: COMPANY OVERVIEW
  • TABLE 580 MERCK KGAA: PRODUCTS OFFERED
  • TABLE 581 MERCK KGAA: DEALS, JANUARY 2023-APRIL 2026
  • TABLE 582 MERCK KGAA: EXPANSIONS, JANUARY 2023-APRIL 2026
  • TABLE 583 HOLOGIC, INC.: COMPANY OVERVIEW
  • TABLE 584 HOLOGIC, INC.: PRODUCTS OFFERED
  • TABLE 585 EUROBIO SCIENTIFIC: COMPANY OVERVIEW
  • TABLE 586 BIOFORTUNA LIMITED: COMPANY OVERVIEW
  • TABLE 587 BAG DIAGNOSTICS GMBH: COMPANY OVERVIEW
  • TABLE 588 FUJIREBIO: COMPANY OVERVIEW
  • TABLE 589 HISTOGENETICS LLC: COMPANY OVERVIEW
  • TABLE 590 PACBIO: COMPANY OVERVIEW
  • TABLE 591 TBG BIOTECHNOLOGY CORP: COMPANY OVERVIEW
  • TABLE 592 SCISCO GENETICS, INC.: COMPANY OVERVIEW
  • TABLE 593 INNO-TRAIN DIAGNOSTIK GMBH: COMPANY OVERVIEW
  • TABLE 594 BIONOBIS: COMPANY OVERVIEW
  • TABLE 595 TAKARA BIO INC.: COMPANY OVERVIEW
  • TABLE 596 KRISHGEN BIOSYSTEMS PRIVATE LIMITED: COMPANY OVERVIEW
  • TABLE 597 PROIMMUNE LTD.: COMPANY OVERVIEW
  • TABLE 598 TRANSPLANT DIAGNOSTICS MARKET: RISK ASSESSMENT

List of Figures

  • FIGURE 1 TRANSPLANT DIAGNOSTICS MARKET SEGMENTATION & REGIONAL SCOPE
  • FIGURE 2 KEY INSIGHTS & MARKET HIGHLIGHTS
  • FIGURE 3 GLOBAL TRANSPLANT DIAGNOSTICS MARKET, 2024-2031
  • FIGURE 4 MAJOR STRATEGIES ADOPTED BY KEY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET, 2023-2025
  • FIGURE 5 DISRUPTIVE TRENDS IMPACTING GROWTH OF TRANSPLANT DIAGNOSTICS MARKET
  • FIGURE 6 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS IN TRANSPLANT DIAGNOSTICS MARKET, 2025
  • FIGURE 7 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 8 RISING CASES OF INFECTIOUS DISEASES TO DRIVE MARKET
  • FIGURE 9 REAGENTS & CONSUMABLES SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 10 MOLECULAR ASSAYS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 11 DIAGNOSTIC APPLICATIONS SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 12 SOLID ORGAN TRANSPLANTATION SEGMENT TO DOMINATE MARKET DURING FORECAST PERIOD
  • FIGURE 13 INDEPENDENT REFERENCE LABORATORIES SEGMENT TO LEAD MARKET DURING FORECAST PERIOD
  • FIGURE 14 ASIA PACIFIC TO REGISTER HIGHEST GROWTH DURING FORECAST PERIOD
  • FIGURE 15 TRANSPLANT DIAGNOSTICS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
  • FIGURE 16 TRANSPLANT DIAGNOSTICS MARKET: PORTER'S FIVE FORCES ANALYSIS
  • FIGURE 17 TRANSPLANT DIAGNOSTICS MARKET: SUPPLY CHAIN ANALYSIS
  • FIGURE 18 TRANSPLANT DIAGNOSTICS MARKET: VALUE CHAIN ANALYSIS
  • FIGURE 19 TRANSPLANT DIAGNOSTICS MARKET: ECOSYSTEM ANALYSIS
  • FIGURE 20 TRANSPLANT DIAGNOSTICS MARKET: TRENDS & DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
  • FIGURE 21 NUMBER OF DEALS & FUNDING ACTIVITIES IN TRANSPLANT DIAGNOSTICS MARKET
  • FIGURE 22 PATENT ANALYSIS FOR TRANSPLANT DIAGNOSTICS, JANUARY 2016-DECEMBER 2025
  • FIGURE 23 MARKET POTENTIAL OF AI IN TRANSPLANT DIAGNOSTICS MARKET
  • FIGURE 24 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS, BY PRODUCT & SERVICE
  • FIGURE 25 KEY BUYING CRITERIA, BY PRODUCT & SERVICE
  • FIGURE 26 NORTH AMERICA: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 27 ASIA PACIFIC: TRANSPLANT DIAGNOSTICS MARKET SNAPSHOT
  • FIGURE 28 REVENUE ANALYSIS OF KEY PLAYERS IN TRANSPLANT DIAGNOSTICS MARKET, 2023-2025 (USD MILLION)
  • FIGURE 29 TRANSPLANT DIAGNOSTICS MARKET SHARE ANALYSIS, 2025 (GLOBAL)
  • FIGURE 30 TRANSPLANT DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2025
  • FIGURE 31 TRANSPLANT DIAGNOSTICS MARKET: COMPANY FOOTPRINT
  • FIGURE 32 TRANSPLANT DIAGNOSTICS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2025
  • FIGURE 33 EV/EBITDA OF KEY VENDORS
  • FIGURE 34 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
  • FIGURE 35 TRANSPLANT DIAGNOSTICS MARKET: BRAND/PRODUCT COMPARISON FOR TRANSPLANT INSTRUMENTS
  • FIGURE 36 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 37 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2025)
  • FIGURE 38 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 39 QIAGEN N.V.: COMPANY SNAPSHOT (2025)
  • FIGURE 40 BIOMERIEUX: COMPANY SNAPSHOT (2025)
  • FIGURE 41 ILLUMINA, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 42 BECTON, DICKINSON AND COMPANY: COMPANY SNAPSHOT (2025)
  • FIGURE 43 CAREDX, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 44 DIASORIN S.P.A.: COMPANY SNAPSHOT (2025)
  • FIGURE 45 WERFEN: COMPANY SNAPSHOT (2025)
  • FIGURE 46 MERCK KGAA: COMPANY SNAPSHOT (2025)
  • FIGURE 47 HOLOGIC, INC.: COMPANY SNAPSHOT (2025)
  • FIGURE 48 RESEARCH DESIGN
  • FIGURE 49 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
  • FIGURE 50 TOP-DOWN APPROACH
  • FIGURE 51 DATA TRIANGULATION
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!